JP2005511038A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511038A5
JP2005511038A5 JP2003548768A JP2003548768A JP2005511038A5 JP 2005511038 A5 JP2005511038 A5 JP 2005511038A5 JP 2003548768 A JP2003548768 A JP 2003548768A JP 2003548768 A JP2003548768 A JP 2003548768A JP 2005511038 A5 JP2005511038 A5 JP 2005511038A5
Authority
JP
Japan
Prior art keywords
factor viii
human factor
modified human
seq
substitutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003548768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/037884 external-priority patent/WO2003047507A2/en
Publication of JP2005511038A publication Critical patent/JP2005511038A/ja
Publication of JP2005511038A5 publication Critical patent/JP2005511038A5/ja
Pending legal-status Critical Current

Links

JP2003548768A 2001-11-30 2002-11-27 第viii因子c2ドメインのバリアント Pending JP2005511038A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33456901P 2001-11-30 2001-11-30
PCT/US2002/037884 WO2003047507A2 (en) 2001-11-30 2002-11-27 Factor viii c2 domain variants

Publications (2)

Publication Number Publication Date
JP2005511038A JP2005511038A (ja) 2005-04-28
JP2005511038A5 true JP2005511038A5 (enExample) 2005-12-22

Family

ID=23307813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003548768A Pending JP2005511038A (ja) 2001-11-30 2002-11-27 第viii因子c2ドメインのバリアント

Country Status (8)

Country Link
US (1) US20040249134A1 (enExample)
EP (1) EP1456235A4 (enExample)
JP (1) JP2005511038A (enExample)
CN (1) CN1630666A (enExample)
AU (1) AU2002364509A1 (enExample)
CA (1) CA2462966A1 (enExample)
MX (1) MXPA04005079A (enExample)
WO (1) WO2003047507A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
IT1394522B1 (it) 2009-01-09 2012-07-05 Invatec Technology Ct Gmbh Dispositivo medicale con rilascio di farmaco
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
CN104788557A (zh) * 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
EP3107561A4 (en) * 2014-02-19 2017-12-20 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2025164792A1 (ja) * 2024-02-02 2025-08-07 学校法人自治医科大学 高比活性/高分泌発現型の第viii因子改変体、高発現型の第viii因子コード核酸及びそれらの用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej

Similar Documents

Publication Publication Date Title
JP2004525608A5 (enExample)
Arai et al. Amino‐acid sequence of feather keratin from fowl
Benedetti X‐ray crystallography of peptides: The contributions of the Italian laboratories
RU2003107100A (ru) Модифицированный фактор viii
Mtwisha et al. HSP 12 is a LEA-like protein in Saccharomyces cerevisiae
CN115443288A (zh) 一种免疫球蛋白降解酶IdeE的突变体
JP2018510622A5 (enExample)
CZ286889B6 (en) Parathormone derivatives and pharmaceutical preparations in which they are comprised
ATE509943T1 (de) Peptidreinigung mittels metallionenaffinitätschromatographie
HU205368B (en) Process for producing peptides with antiaggregational effect and pharmaceutical compositions comprising same as active ingredient
US4659694A (en) Prothymosin alpha
RU2020116307A (ru) Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса
JP2020517260A5 (enExample)
JP2015504052A5 (enExample)
JP2007535910A5 (enExample)
US20100099113A1 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
Browning et al. Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers
JP2004505640A5 (enExample)
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
WO2003090667A3 (fr) Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16
RU2010120571A (ru) Тимус-специфический белок
WO1995000546A1 (en) Endothelin-antagonizing peptide
JP2023544300A5 (enExample)
JP2003334088A5 (enExample)
US20090215025A1 (en) Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins